Early Methylene Blue for Mortality Reduction in High-Dose VasoPREssor-Dependent Septic Shock (EMPRESS): protocol for a multicenter randomized controlled trial. (2026)

Peer-Reviewed Study · Luo JC, Ma L, Luo MH, Ibarra-Estrada M, Yan PJ, Zhang ZA, Meng M, Kattan E, Lu S, Pan C, Teboul JL, Hernández G, Huang XB · January 24, 2026

Luo JC et al., 2026-01-24: Protocol for the EMPRESS multicentre randomized trial in China: 566 patients with high-dose vasopressor-dependent septic shock randomized to methylene blue or 5% dextrose.

A total of 566 patients will be randomized 1:1 to receive MB treatment (2 mg/kg loading dose followed by 0.25 mg/kg/h maintenance infusion for up to 48 h or 4 h after vasopressor discontinuation) or equal volume 5% dextrose control.

Luo JC et al., 2026-01-24: Protocol for the EMPRESS multicentre randomized trial in China: 566 patients with high-dose vasopressor-dependent septic shock randomized to methylene blue or 5% dextrose. C5. Study type: randomized controlled trial protocol (registered, no results). N planned 566, multiple centres in China; Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital. Dose as quoted: 2 mg/kg loading dose then 0.25 mg/kg/h for up to 48 h or 4 h after vasopressor discontinuation; comparator 5% dextrose; primary endpoint 28-day mortality. Registration ChiCTR2500112352. Recorded as PARTLY SUPPORTS per the registered-no-results rule. Scand J Trauma Resusc Emerg Med 2026;34:44.